DEP® irinotecan outperforms irinotecan in multiple cancer models
Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its proprietary DEP® irinotecan has demonstrated significantly better anti‑tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models.
Starpharma receives DEP® milestone from AstraZeneca
Starpharma today announced it has received A$2.6 million from AstraZeneca following the achievement of the final preclinical milestone for its first DEP® candidate, a highly novel oncology molecule from AstraZeneca’s portfolio.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2017.
Starpharma featured on Ticky on Sky Business News
Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.
AstraZeneca DEP® candidate advance triggers milestone to Starpharma
Starpharma announced the achievement of a key preclinical milestone for its DEP® drug delivery technology in combination with a proprietary oncology molecule from AstraZeneca.
Melbourne-based company develops world's first anti-viral condom
The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.
Ansell launches VivaGel® condom in Canada
Starpharma is pleased to announce the VivaGel® condom has been launched in Canada by Ansell under the LifeStyles® Dual Protect™ brand.
VivaGel BV phase 3 trials for prevention of BV completed
Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.
VivaGel® BV phase 3 trials for prevention of BV completed
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.
Interim Report and Half-Yearly Financial Results
Starpharma released its interim report and financial results for the half-year ended 31 December 2016.
Financial Summary
- Reported loss of $9.0M (Dec 2015: $10.0M)
- R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
- Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
- Receipt of $3.5M R&D tax incentive refund from FY16